Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek

Dow Jones12-21 05:09

By Katherine Hamilton

Vertex Pharmaceuticals said the Food and Drug Administration approved a new treatment for cystic fibrosis.

The treatment, called alyftrek, is designed to treat cystic fibrosis in patients six years and older who have at least one F508del mutation or another mutation that is responsive to alyftrek. It is the first once-daily treatment for cystic fibrosis transmembrane conductance regulator (CFTR) modulator, Vertex said.

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 20, 2024 16:09 ET (21:09 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment